2016
DOI: 10.1016/j.jval.2016.08.257
|View full text |Cite
|
Sign up to set email alerts
|

Economic Evaluation of Cancer Medicines Usage at Uganda Cancer Institute

Abstract: The study was cross sectional study. The patients were randomly selected by taking the 6th patient in the treatment / dispensing queue, to participate in the study. 25 patients per day were randomly selected out of the 98 patients who were receiving chemotherapy. The study population was of 385 patients . Results: The cost of medicines supplied by government, donations and out of pocket cost were Shs. 103,000,000 (€ 26,410), Shs.153,000,000 (€ 39,230) and Shs.30,700,000 (€ 7,871) respectively. The proportions … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…4 The delay could be due to the fact that many breast cancer patients, particularly in rural Ugandan settings, are unable to access the only public health facility for specialized cancer treatment. 5 Furthermore, while 92.7% of the cost of medicines used at the Uganda Cancer Institute is covered by the government of Republic of Uganda, 6 the drugs are out of stock most of the time and patients have to buy them. Those who cannot afford these medicines discontinue treatment because of the economic burden.…”
Section: Introductionmentioning
confidence: 99%
“…4 The delay could be due to the fact that many breast cancer patients, particularly in rural Ugandan settings, are unable to access the only public health facility for specialized cancer treatment. 5 Furthermore, while 92.7% of the cost of medicines used at the Uganda Cancer Institute is covered by the government of Republic of Uganda, 6 the drugs are out of stock most of the time and patients have to buy them. Those who cannot afford these medicines discontinue treatment because of the economic burden.…”
Section: Introductionmentioning
confidence: 99%